Product Usage:This PRODUCT IS INTENDED AS A RESEARCH CHEMICAL ONLY
hospitalization required Maintenance of Remission: Immunomodulators (azathioprine, 6-MP, methotrexate) for steroid-dependent or frequently-relapsing disease Biologic monotherapy or combination therapy (biologic + immunomodulator) for moderate-to-severe disease Step-up or top-down approach based on disease severity, patient risk factors, and prior therapy Biologic Therapy Targets: TNF-: Infliximab (IV), adalimumab (SC), certolizumab pegol (SC) IL-12/23: Ustekinumab (IV induction, SC maintenance) Integrin: Vedolizumab (IV) IL-23: Risankizumab (IV induction, SC maintenance) JAK inhibition: Upadacitinib (oral) Surgical Management Surgery is indicated in approximately 7080% of patients with Crohns disease over their lifetime, per StatPearls
Perioperative BPC-157 administration in surgical patients represents a potential application requiring safety and efficacy validation in clinical trials with surgical outcome measures
Cook completed his surgical training at UPMC Pinnacle, followed by a three-year plastic surgery fellowship at Cleveland Clinic Florida and an elite Hand and Microsurgery fellowship at the University of Miami
Stable gastric pentadecapeptide BPC 157 can improve the healing course of spinal cord injury and lead to functional recovery in rats
